Ftse Mib
33.179,69
-0,02%
DAX
18.293,00
0,48%
S&P 500
5.513,29
0,55%
NASDAQ
17.984,02
0,70%
Bitcoin
60.756,70
-1,39%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Compass Therapeutics Inc (CMPX) Compass Therapeutics Inc (CMPX) Notizie

CMPX

Compass Therapeutics (CMPX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CMPX
DataOraFonteTitoloSimboloCompagnia
17/06/202414:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMPXCompass Therapeutics Inc
30/05/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:CMPXCompass Therapeutics Inc
28/05/202422:10GlobeNewswire Inc.Compass Therapeutics Announces CEO TransitionNASDAQ:CMPXCompass Therapeutics Inc
23/05/202423:05GlobeNewswire Inc.Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual MeetNASDAQ:CMPXCompass Therapeutics Inc
14/05/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:CMPXCompass Therapeutics Inc
13/05/202414:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMPXCompass Therapeutics Inc
13/05/202414:00GlobeNewswire Inc.Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
25/04/202414:00GlobeNewswire Inc.Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedNASDAQ:CMPXCompass Therapeutics Inc
16/04/202414:00GlobeNewswire Inc.Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsNASDAQ:CMPXCompass Therapeutics Inc
12/04/202414:00GlobeNewswire Inc.Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ConferenceNASDAQ:CMPXCompass Therapeutics Inc
10/04/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Stifel Targeted Oncology DaysNASDAQ:CMPXCompass Therapeutics Inc
09/04/202418:00GlobeNewswire Inc.Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:CMPXCompass Therapeutics Inc
21/03/202414:00GlobeNewswire Inc.Compass Therapeutics Reports 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
11/03/202415:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMPXCompass Therapeutics Inc
29/02/202414:00GlobeNewswire Inc.Compass Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:CMPXCompass Therapeutics Inc
28/02/202414:00GlobeNewswire Inc.Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical TrialNASDAQ:CMPXCompass Therapeutics Inc
05/01/202414:00GlobeNewswire Inc.Compass Therapeutics Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
09/11/202313:30GlobeNewswire Inc.Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
07/11/202314:00GlobeNewswire Inc.Compass Therapeutics to Participate in Upcoming Investor EventsNASDAQ:CMPXCompass Therapeutics Inc
03/08/202314:00GlobeNewswire Inc.Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
22/06/202322:05GlobeNewswire Inc.Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:CMPXCompass Therapeutics Inc
04/05/202314:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CMPXCompass Therapeutics Inc
04/05/202314:30GlobeNewswire Inc.Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
27/04/202322:26Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:CMPXCompass Therapeutics Inc
26/04/202314:30GlobeNewswire Inc.Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQNASDAQ:CMPXCompass Therapeutics Inc
19/04/202314:30GlobeNewswire Inc.Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysNASDAQ:CMPXCompass Therapeutics Inc
28/03/202314:30GlobeNewswire Inc.Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology SymposiumNASDAQ:CMPXCompass Therapeutics Inc
15/03/202313:30GlobeNewswire Inc.Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:CMPXCompass Therapeutics Inc
14/02/202320:59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CMPXCompass Therapeutics Inc
10/02/202322:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CMPXCompass Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CMPX

La tua Cronologia

TSXV
RSG
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network